Endoscopy
DOI: 10.1055/a-2678-7367
Innovations and brief communications

A novel colonoscope with 230-degree extra-wide field of view optics: a prospective, first-in-human pilot study

Horst Neuhaus
1   Department of Gastroenterology, RKM740 Interdisciplinary Care Clinic, Duesseldorf, Germany
,
Moritz Schiemer
2   Department of Gastroenterology, Hepatology and Endocrinology, Robert Bosch Hospital, Stuttgart, Germany
,
Johannes Grossmann
1   Department of Gastroenterology, RKM740 Interdisciplinary Care Clinic, Duesseldorf, Germany
,
Arthur Schmidt
3   Department of Gastroenterology, Hepatology and Endocrinology, Robert Bosch Hospital, Stuttgart, Germany (Ringgold ID: RIN15000)
› Author Affiliations
Clinical Trial: Registration number (trial ID): NCT06483503, Trial registry: ClinicalTrials.gov (http://www.clinicaltrials.gov/), Type of Study: Bicentric prospective clinical pilot trial
Preview

Background and aims: A model-based trial of a novel colonoscope with extra-wide field of view (EFOV) optics demonstrated a higher polyp detection rate compared to a standard colonoscope [1]. We report on the first-in-human study assessing its clinical utility. Methods: This bicentric prospective pilot trial included patients scheduled for colorectal cancer screening (CRCS), evaluation of a positive fecal immunochemical test (FIT), or polyp surveillance. The primary endpoint was the cecal intubation rate with the EFOV colonoscope. Secondary endpoints included intubation rate of the terminal ileum, procedure time, rates for detection of polyps (PDR), adenomas (ADR), sessile serrated lesions (SSLDR), adenomas per colonoscopy (APC), therapeutic success and adverse events. Results: Sixty-four patients were enrolled. Indications were CRCS (n=48) or polyp surveillance (n=16). The cecum was reached in 64 of 64 patients (100%, 95%CI 94.4 to 100.0) within a median time of 5.0 (range 2.0 to 20.0) minutes. The terminal ileum could be intubated in 96.9% (95%CI 89.2 to 99.6) of cases. Eighty-four polyps were detected and removed in 43 of 64 patients (PDR = 67%). The ADR, SSLDR and APC were 44%, 17%, and 0.81 (95%CI 0.5 to 1.1). No adverse events occurred. Conclusions: This first-in-human study shows that the EFOV colonoscope can be effectively and safely used in clinical practice. It promises improved detection of hidden polyps.



Publication History

Received: 12 April 2025

Accepted after revision: 06 August 2025

Accepted Manuscript online:
06 August 2025

© . Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany